WO2020106074A1 - 창상치료용 약학조성물 - Google Patents
창상치료용 약학조성물Info
- Publication number
- WO2020106074A1 WO2020106074A1 PCT/KR2019/016011 KR2019016011W WO2020106074A1 WO 2020106074 A1 WO2020106074 A1 WO 2020106074A1 KR 2019016011 W KR2019016011 W KR 2019016011W WO 2020106074 A1 WO2020106074 A1 WO 2020106074A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- plasma
- silk
- wound
- composition
- wounds
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- EGF epidermal growth factor
- Acid and basic FGF acidic and basic fibroblast growth factor
- TGF- ⁇ and TGF- ⁇ transformation factors
- IGF-I and II growth factors
- adhesion factors such as fibronectin, laminrin, vitronectin, retinoids and similar compounds are known.
- Cytokines have been identified as growth factors related to wound healing, and typical examples are keratinocytes and fibroblasts, which promote the growth of epithelial cells (basic fibrogrowth factor) and platelet endothelial tissue. It is produced in platelet-derived growth factor (PDGF), fibroblasts and platelets that are produced in the platelet-derived growth factor (PDGF) that promotes the growth of epithelial cells along with epidermal growth factor (EGF). Transforming growth factor ( ⁇ , TGF- ⁇ ) that promotes the growth of epithelial cells, fibroblast growth factor (FGF) and macrophage, which are produced in the salivary gland stimulation line to promote the proliferation of epithelial cells.
- PDGF platelet-derived growth factor
- fibroblasts fibroblasts and platelets that are produced in the platelet-derived growth factor (PDGF) that promotes the growth of epithelial cells along with epidermal growth factor (EGF).
- Transforming growth factor ( ⁇ , TGF- ⁇ ) that promotes
- interleukin-1 which is produced by epithelial cells and promotes epithelial cell growth and motility.
- Becaplermin which is marketed as a wound treatment for topical administration under the trade name Regranex by Johnson & Johnson, is a genetically engineered PDGF.
- European Patent No. 0575484B1 discloses a pharmaceutical composition comprising PDGF and dexamethasone and for regeneration and treatment of tissue in mammals.
- U.S. Patent No. 5901606 discloses a pharmaceutical composition for the treatment of wounds comprising TGF- ⁇ .
- International patent publication WO 96/30038 discloses a pharmaceutical composition for wound treatment comprising TGF- ⁇ , fibric acid and an antioxidant.
- U.S. Patent No. 5183805 discloses a pharmaceutical composition that has the effect of regenerating tissue, including EGF.
- Japanese Patent No. 05070365 and U.S. Patent No. 6165978 disclose wound treatments comprising FGF.
- fibronectin glycoprotein found in plasma
- the plasma blood plasma
- the wound treatment by confirming that it exhibits a wound healing effect by normalizing abnormal cells and various cell active substances in the wound area (Republic of Korea Patent No. 0518152 and Republic of Korea Patent) 2007-0113876).
- Plasma is a pale yellow liquid in which mammalian blood is separated from tangible components, ie, cells and cell fragments. Plasma is placed in the blood and centrifuged or left at low temperature (approximately 0 °C) to put the plasma in the upper part and the type in the lower part. It is divided into ingredients. In this case, the proportion of plasma is slightly different depending on the sex, but it is about 55%.
- the composition of plasma is about 90% water, 7-8% plasma protein, and other lipids, saccharides, inorganic salts, and non-proteinaceous properties. As a nitrogen compound, it contains urea, amino acid, and uric acid.
- Most of the plasma proteins are made in the liver, mainly albumin and globulin, but also contain fibrinogen related to blood clotting.
- Lipids are cholesterol, lecithin, etc.
- Inorganic salts are sodium, chlorine, potassium, calcium, magnesium, etc. , Its composition is similar to seawater and plays an important role in maintaining the osmotic pressure in the body to normal.
- the total amount and composition of plasma changes markedly depending on the disease, it is used to diagnose the disease or to know the condition of the disease.
- Plasma has many uses as described above, and its use is infinite. Especially, plasma contains active substances with high medical uses such as albumin and fibrinogen, and is widely used as a source of these substances. There is a disadvantage that is not economical because it must be separated from the blood.
- sericin a kind of silk protein
- silk glue a kind of silk protein
- the cocoon fiber is covered with two layers of fibroin with three layers of sericin.
- E-cramer separated from the cocoon fiber.
- the rough and hard feeling of raw silk is due to the adherence of sericin.
- sericin melts and disappears, giving it a unique texture.
- Sericin has a lot of distinct serine of about 37 mol% of amino acid composition, and it has the characteristic of gelling when dissolved in hot water and cooled.
- spider silk proteins include dragline proteins and / or flake proteins
- dragline silks are used by orb weaving spiders to frame and radially build their nets, and continuously move back. It's the lifeline that makes it possible. For this purpose, high tensile strength and elasticity are required. The combination of these properties showed a higher tensile than known materials.
- Dragline silk is generally composed of two major proteins, and the primary structure of the proteins shares a common repetitive architecture. A viscous silk formed by a flagelliform gland, the helical capture of an orb web consisting partly of a silk called flaky silk is elastic and can stretch to a length of three times before it breaks, It is about half the tensile strength of the dragline silk.
- the variation of a single repeat unit can include up to 60 amino acids, repeated many times to represent the largest portion of the spider silk sequence. These repeat units contain a limited set of distinct amino acid motifs. One motif found in all dragline silk repeat units is typically a block of 6-9 alanine residues. In silk threads, several polyalanine motifs form crystalline ⁇ -sheet stacks that result in a tensile strength.
- Silk protein is mainly used to cover wounds from the outside by using it as a covering material, and it is a technology to produce a silk protein in the form of a gel and use it as a wound coating (Republic of Korea Patent No. 1,617,075), or silk protein Although it is known to produce a film in a membrane form and use it as a wound coating (Republic of Korea Patent No. 0,315,168), the effect of directly treating wounds is unknown.
- a wound treatment agent containing a plasma component and a silk protein is prepared, and when applied to the wound area, it is confirmed that the present invention shows excellent wound repair effect. It was completed.
- An object of the present invention is to provide an economical and effective pharmaceutical composition for wound healing.
- Another object of the present invention is to provide a method for treating wounds comprising the step of administering a plasma or serum component and a silk protein.
- Another object of the present invention is to provide the use of plasma or serum components and silk proteins for the treatment of wounds.
- Another object of the present invention is to provide the use of plasma or serum components and silk proteins for the manufacture of a medicament for wound healing.
- the present invention provides a pharmaceutical composition for treating wounds containing plasma or serum components and silk protein as an active ingredient.
- the present invention also provides a method of treating wounds comprising the step of administering a plasma or serum component and a silk protein.
- the present invention also provides the use of plasma or serum components and silk proteins for the treatment of wounds.
- the present invention also provides the use of plasma or serum components and silk proteins for the manufacture of a medicament for wound healing.
- Figure 1 shows the results of confirming the healing effect of plasma components on the scratch wound of NIH3T3 cells, fibroblasts of mice.
- Figure 2 shows the results confirming the healing effect of plasma components and sericin protein on scratch wounds of NIH3T3 cells, fibroblasts of rats.
- Figure 3 shows the results confirming the healing effect of plasma components and recombinant spider silk protein on the scratch wound of NIH3T3 cells, fibroblasts of rats.
- the wound repair effect was superior to that when the plasma component or the silk protein was applied.
- the present invention in one aspect, relates to a pharmaceutical composition for treating wounds that contains a plasma or serum component and silk protein as an active ingredient.
- the pH of the composition may be characterized as being 3.5 to 6.5, and the plasma or serum may be characterized as being derived from human or livestock.
- the plasma component may be a plasma component obtained by separating albumin, fibrinogen, and thrombin, heparin, antithrombin III, blood coagulation factor 2, blood clotting factor 8, blood clotting factor 9, and IgG It may be characterized in that one or more selected from the group consisting of is additionally removed.
- the plasma or serum component may be characterized in that it is a lyophilized formulation, and the plasma or serum component in the composition may be characterized as contained in 0.001 to 99.999%.
- the silk protein in the composition may be characterized in that it contains 0.001% to 99.999%.
- the composition preferably contains 0.01 to 10% of the plasma component, and may contain 0.001 to 10% of the silk protein, more preferably 0.1 to 2% of the plasma component, and the silk protein. It may contain 0.01 to 1%, even more preferably, it contains 0.2 to 1% of plasma components, and it is preferable to contain 0.02 to 0.1% of silk protein.
- the wound treatment effect when the plasma content is 10% or more, the wound treatment effect cannot be improved compared to the added amount, and when the plasma content is less than 0.01%, the wound treatment effect cannot be expected.
- the silk protein when the silk protein is contained in an amount of 10% or more, the wound treatment effect cannot be improved compared to the added amount, and when the silk protein is contained in an amount of less than 0.001%, the wound treatment effect cannot be expected.
- the silk protein may be characterized in that it is a natural or recombinant silk protein, and the silk protein is dragline silk, elastin, silk fibroin, silk fibroin, byssus), sericin, flagelliform silk, and collagen (collagen).
- the silk protein may be characterized in that it has a structure in which the glycine or serine content of 1% or more of the silk repeat unit peptide is repeated 1 to 160 times.
- the silk protein may be characterized by having a molecular weight of 5 ⁇ 300kDa.
- the recombinant silk protein may be characterized as a recombinant spider protein.
- the recombinant spider silk protein can be prepared by the method described in Korean Patent Registration No. 10-1317420B1, and has a structure in which peptides having the following sequence of SEQ ID NO: 1 or SEQ ID NO: 2 are repeated 1 to 96 times.
- Eggplant can use a high molecular weight recombinant spider silk protein.
- the wound is a non-healing traumatic wound, destruction of tissue by irradiation, abrasion, bone mass, laceration, rupture wound, penetrating wound, gunshot wound, cut, burn, frostbite, skin ulcer, skin dryness, skin keratosis
- Conditions related to diabetes and poor circulation such as cracks, bursts, dermatitis, pain caused by dermatosis, surgical or vascular disease wounds, bruises, corneal wounds, bedsores, diabetic skin disorders, chronic ulcers, sutures after plastic surgery It can be characterized as being selected from the group comprising sites, spinal injury wounds, gynecological wounds, chemical wounds and acne.
- the formulation of the therapeutic composition may be characterized in that any one form selected from the group consisting of cream, ointment, gel, liquid, powder and patch.
- the invention also relates to a method of treating wounds comprising the step of administering a plasma or serum component and a silk protein.
- the present invention relates to the use of plasma or serum components and silk proteins for the treatment of wounds.
- the present invention relates to the use of plasma or serum components and silk proteins for the manufacture of a medicament for wound healing.
- the wound refers to a condition in which the living body is damaged, and a pathology in which tissue forming an internal or external surface of the living body, for example, skin, muscle, nerve tissue, bone, soft tissue, internal organs, or vascular tissue is divided or destroyed. Covers enemy status.
- wounds include, but are not limited to, non-healing traumatic wounds, tissue destruction by irradiation, abrasion, bone mass, laceration, avulsion, and penetrated wound.
- Gun shot wound cuts, burns, frostbite, bruises, skin ulcers, dry skin, keratosis, cracks, bursts, dermatitis, pain caused by dermatosis, surgery, vascular disease wounds, cornea
- wounds such as wounds, bedsores, spear wounds, diabetic skin disorders, and conditions related to diabetes and poor circulation, chronic ulcers, sutures after plastic surgery, spinal injury wounds, gynecological wounds, chemical wounds, and acne. Damage to any part is included.
- the formulations according to the invention can be very useful for repairing, repairing, improving, accelerating, or curing such damaged tissue.
- the plasma used in the present invention includes those separated from the blood of all species of mammals, including humans, and blood such as livestock, other primates, rodents, etc., including sheep, goats, pigs, horses, dogs, and cattle.
- plasma can be easily separated from the blood by conventional well-known methods, such as centrifugation, sedimentation, or filtration. Centrifugation can be performed under conditions suitable for sedimentation of blood cells from plasma. For example, the blood is centrifuged at about 1,400 g for about 10 minutes, and it is sufficient to precipitate not only blood cells and white blood cells but also substantially all cell fragments containing platelets. Supernatant containing plasma is precipitated by standard techniques. Can be easily separated from the cells
- the filtration method may be performed by passing blood through a filter suitable for separating blood cells from plasma, and the filter is preferably a microporous membrane capable of easily permeating proteins.
- a method of preserving the plasma in various states before use is known, for example, a fresh freezing agent, a cryoprecipitating agent, a lyophilizing agent, or a thickening agent.
- all the above-described types of plasma can be used.
- composition according to the present invention can be applied directly to the wound as a liquid or powder, that is, it can be scattered over the wound site. In the case of a sheet, it is applied to the wound site. Prevents the therapeutic effect from diminishing.
- the dressing is commercially available or any commercially available one can be used. Examples of commercially available dressings include Compeel, Duoderm, Tagaderm and Opsite.
- compositions containing a pharmaceutically effective amount of a plasma component as an active ingredient according to the present invention can be formulated in a variety of different forms with a pharmaceutically acceptable carrier. Formulation can be performed according to methods known in the art. Can be. Forms of the formulation include, but are not limited to, liquid coating agents, sprays, lotions, creams, gels, pasta agents, linen agents, ointments, aerosols, powders, and transdermal absorbers. Is described in Remington's Pharmaceutical Science, 15th Edition, 1975, Mack Publishing Company, Easton, Pennsylvania 18042 (Chapter 87: Blaug, Seymour), a prescription generally known to all pharmaceutical chemistries.
- hydrocarbons such as petrolatum, liquid paraffin, gelled hydrocarbons (alias plastibase); Animal and vegetable oils such as medium-chain fatty acid triglyceride, pork, hard fat, and cacao butter; Higher fatty acid alcohols and fatty acids such as cetanol, stearyl alcohol, stearic acid and isopropyl palmitate, and esters thereof; Water-soluble bases such as macrogol (polyethylene glycol), 1,3-butylene glycol, glycerol, gelatin, white sugar, sugar alcohol; Emulsifiers such as glycerin fatty acid esters, polyoxyl stearate, and polyoxyethylene cured castor oil; Adhesives such as acrylic esters and sodium alginate; Propellants such as liquefied petroleum gas and carbon dioxide; Preservatives, such as paraoxybenzoic acid esters, etc.
- hydrocarbons such as petrolatum, liquid paraffin, gelled hydrocarbons (alias plastibase); Animal and vegetable oils such as medium
- the external preparation of this invention can be manufactured according to a conventional method using these.
- stabilizers, fragrances, colorants, pH adjusters, diluents, surfactants, preservatives , Antioxidants and the like may be blended as needed.
- the external preparation of the present invention can be applied to the local wound by a conventional method.
- the external preparation according to the present invention can be used by being adhered to a solid support such as a wound peeling cover of a conventional band-aid, etc. Adhesion is achieved by saturating the solid support with a plasma fraction from which commercial components have been removed, followed by dehydration.
- the solid support is first coated with an adhesive layer to improve adhesion of the plasma component from which the commercial component has been removed to the solid support.
- the adhesive include polyacrylate and cyanoacrylate.
- the pharmaceutical composition according to the present invention can be formulated in the form of a liquid coating agent by mixing the plasma powder and physiological saline in a constant volume ratio and adjusting the pH to 3.5 to 6.5.
- the pharmaceutical composition according to the present invention is As a preferred embodiment, the pharmaceutical composition according to the present invention adjusts the pH of the ointment agent to 3.5 to 6.5 by mixing the plasma powder of the present invention with a water-soluble ointment agent and adding physiological saline thereto. To formulate.
- compositions or microspheres can be used in the present invention to accelerate healing of wounds.
- US Pat. Nos. 5,264,207, WO2000 / 24378, WO96 / 13164 and WO 94/13333 include one or more active pharmaceutical or cosmetic substances. Microspheres of polymers that act as carriers for are described.
- the pharmaceutical composition of the present invention can be used to treat various wound symptoms in mammals, which include infection status, malignancy, macrovascular artery deficiency, small vascular artery deficiency, deep vein blockage or deficiency, superficial vein deficiency, lymphatic vessel disorder, and endogenous circulation shortage. It is effective against most malignant ulcers, including those caused by blood abnormalities, collagen vascular abnormalities, radiation dermatitis, and nutritional causes.
- the pharmaceutically effective amount of the plasma component used in the composition of the present invention refers to the amount of the active ingredient exhibiting the therapeutic effect of wound by normalizing abnormal cells and various cell active substances in the wound site.
- the effective amount may vary depending on the type of wound, the application site, the number of treatments, the treatment time, the formulation, the patient's condition, and the type of supplement.
- the number of times of administration may be 2 times a day to once a week
- the daily effective amount of the pharmaceutical composition of the present invention is 0.01 to 0.1 g / cm2, preferably 0.02 to 0.09 g / cm2, more preferably 0.02 to 0.07 g / cm2.
- the separated plasma was collected in a glass tube to which no anticoagulant such as EDTA or heparin was added, and the plasma was allowed to stand overnight at 4 ° C to remove the precipitated fibrinogen clot using a Pasteur pipette.
- the blood from which the lump had been removed was centrifuged at 4000 rpm at 4 ° C for 20 minutes to obtain a plasma fraction with fibrinogen removed.
- the thrombin present in the plasma fraction from which the fibrinogen was removed was isolated under acidic conditions.
- the pH of the plasma fraction was lowered to 5.1-5.3 using acetic acid solution.
- the solution with the lowered pH was allowed to stand at 20 ° C. for 1 hour to completely precipitate prothrombin, followed by centrifugation at 4200 rpm at 20 ° C. for 20 minutes to remove the precipitated thrombin, thereby obtaining a plasma fraction from which fibrinogen and thrombin were removed.
- the albumin contained in the fibrinogen / thrombin removal plasma fraction was removed according to the manufacturer's method using a SwellGel Blue albumin removal kit (Pierce Biotechnology, USA). After the albumin removal method, a plasma fraction having commercial components removed therefrom was obtained.
- Plasma fraction from which the commercial component obtained in Example 1 was removed was inactivated virus that may be present in the plasma component by continuously performing the following three methods.
- Fibrinogen / thrombin / albumin removal and silk protein peptide addition plasma fractions were irradiated with a total gamma ray of 25kGy at an intensity of 1.8kGy / hr using Cobalt One 60Co at 15 ° C.
- Methylene blue was added at a final concentration of 1 ⁇ M to the plasma fraction of gamma-irradiated fibrinogen / thrombin / albumin removal and silk protein peptide addition, and white light was irradiated at 60,000 lux for 1 hour. The remaining methylene blue was removed by filtration, frozen at -80 ° C for 8 hours, and dried at -48 ° C for 7 days to lyophilize.
- the plasma fraction was sieved, crushed and homogenized, and then water vapor was slowly injected into the stainless steel tank so that the water content was 8% (w / w).
- the water vapor-treated plasma was transferred to a stainless steel cylinder filled with dry nitrogen to remove oxygen, and then heated at 60 ° C. for 10 hours to obtain a plasma fraction in which virus was inactivated.
- Plasma fraction in which the virus obtained in Example 2 was impurized was added with 1N HCl (hydrochloric acid) or 1N NaOH (sodium hydroxide) while stirring to adjust the pH with a pH meter (Orion) to adjust the pH to 5.5, and freeze-dried plasma. Fractions were obtained.
- Lyophilization was lyophilized for 12 hours at -30 ⁇ -40 °C, 40.9 ⁇ 77.5Torr using a general lyophilizer, and slowly progressed by installing a 0.2 ⁇ m antibacterial filter to obtain dried plasma components, and then confirming the wound treatment effect. Used for.
- Recombinant spider silk protein was prepared using the following method.
- Recombinant spider silk protein was prepared by the method described in the prior patent (Korea Patent No. 10-1317420B1) for producing a recombinant silk protein.
- a high-molecular weight recombinant silk or silk-like protein having a structure in which the peptide having the sequence of SEQ ID NO: 1 was repeated K times 48 times was used.
- NIH3T3 cell line (KCTC 4612), which is a mouse fibroblast. Seed NIH3T3 cells in a cell culture plate at 500,000 / plate concentration, 10% fetal bovine serum (FBS, Thermo Fisher) and 1% penicillin streptomycine (Pen-strep, Sigma-Aldrich) in DMEM medium (DMEM, Gibco) In a mixed cell growth medium, cells were grown confluently for one week.
- FBS fetal bovine serum
- Pen-strep penicillin streptomycine
- Example 3 In order to confirm the wound healing effect of the wound treatment formulation containing lyophilized plasma fraction and sericin protein (Sigma-Aldrich) obtained in Example 3, a wound regeneration confirmation experiment was conducted using the NIH3T3 cell line in the same manner as in Example 4. .
- Cells were grown confluently in a 10% FBS-containing cell growth medium in the same manner as in Example 4, and after starvation the cells using serum-free medium for one day, grown on a plate to confirm the wound healing effect.
- the cells were scratched, and plasma components were added to serum-free medium at a concentration of 0.5%, and sericin proteins were added at concentrations of 0.05% (w / v) and 0.5% (w / v), respectively.
- As a control group an experiment was performed with the group treated with serum-free medium only and with the group containing only plasma components. After incubating the experimental groups for 12 hours, it was confirmed whether or not the scratch-treated wound was cured.
- plasma fraction (0.5%) and 0.05% sericin protein added group (BP 0.5%, Serer 0.05%)) has a better healing ability than the group containing only plasma components It was confirmed that the optimum concentration of the sericin protein mixture was 0.05%.
- Example 6 Confirmation of the wound healing effect of components containing plasma fraction and recombinant spider silk protein
- Example 3 In order to confirm the wound healing effect of the preparation containing the lyophilized plasma fraction and recombinant silk protein obtained in Example 3, a wound regeneration confirmation experiment was conducted using the NIH3T3 cell line in the same manner as in Example 4.
- Plasma components prepared in serum-free medium were added at a concentration of 0.5% (w / v), and the recombinant silk proteins were added to 0.05% (w / v), 0.1% (w / v) and 0.5% (w /), respectively. v).
- w / v 0.05%
- w / v 0.1%
- w / v 0.5%
- w / 0.5%
- the wound can be more efficiently healed by the synergistic effect of silk proteins and plasma components.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (9)
- 혈장 또는 혈청성분과 실크 단백질을 유효성분으로 함유하는 창상 치료용 약학 조성물.
- 제1항에 있어서, 상기 혈장 또는 혈청은 사람 또는 가축으로부터 유래된 것임을 특징으로 하는 조성물.
- 제1항에 있어서, 상기 실크 단백질은 자연유래 또는 재조합 실크 단백질로부터 유래된 것임을 특징으로 하는 조성물.
- 제1항에 있어서, 상기 실크 단백질은 드레그라인 실크 (dragline silk), 엘라스틴(elastin), 실크 피브로인(silk fibroin), 비서스(byssus), 세리신(sericin), 편모상 실크(flagelliform silk) 및 콜라겐(collagen)로 구성된 군에서 선택된 단백질을 구성하는 반복단위 펩타이드로 구성되는 것을 특징으로 하는 조성물.
- 제1항에 있어서, 상기 실크 단백질은 글리신 혹은 세린 함량이 0.001% 이상인 펩타이드가 1~160회 반복되어 있는 구조를 가지는 것을 특징으로 하는 조성물.
- 제1항에 있어서, 창상은 비-치유 외상성 창상, 방사선조사에 의한 조직의 파괴, 찰과상, 골괴저, 열상, 결출상, 관통상, 총상, 절상, 화상, 동상, 피부궤양, 피부건조, 피부각화증, 갈라짐, 터짐, 피부염, 피부사상균증에 의한 통증, 수술상 또는 혈관질환 창상, 타박상, 각막창상, 욕창, 와창, 당뇨성피부미란과 같은 당뇨병 및 순환불량에 관련된 상태, 만성궤양, 성형수술 후 봉합부위, 척추상해성 창상, 부인과적 창상, 화학적 창상 및 여드름을 포함하는 군에서 선택되는 것임을 특징으로 하는 조성물.
- 제1항에 있어서, 크림, 연고, 겔, 액제, 분말제 및 패치로 구성된 군에서 선택된 어느 하나의 형태인 것을 특징으로 하는 조성물.
- 제1항에 있어서, pH가 3.5~6.5인 것을 특징으로 하는 조성물.
- 제1항에 있어서, 혈장성분은 동결건조 제제인 것을 특징으로 하는 조성물.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/296,301 US20220008463A1 (en) | 2018-11-23 | 2019-11-21 | Pharmaceutical composition for treating wounds |
EP19888039.5A EP3884952A4 (en) | 2018-11-23 | 2019-11-21 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CUTS |
AU2019383263A AU2019383263B2 (en) | 2018-11-23 | 2019-11-21 | Pharmaceutical composition for treating cuts |
CN201980083434.3A CN113194965A (zh) | 2018-11-23 | 2019-11-21 | 用于治疗伤口的药物组合物 |
JP2021529098A JP7309872B2 (ja) | 2018-11-23 | 2019-11-21 | 傷痍治療用医薬組成物 |
SG11202105231UA SG11202105231UA (en) | 2018-11-23 | 2019-11-21 | Pharmaceutical composition for treating wounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2018-0146287 | 2018-11-23 | ||
KR1020180146287A KR102668789B1 (ko) | 2018-11-23 | 2018-11-23 | 창상치료용 약학조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020106074A1 true WO2020106074A1 (ko) | 2020-05-28 |
Family
ID=70773904
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2019/016011 WO2020106074A1 (ko) | 2018-11-23 | 2019-11-21 | 창상치료용 약학조성물 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220008463A1 (ko) |
EP (1) | EP3884952A4 (ko) |
JP (1) | JP7309872B2 (ko) |
KR (1) | KR102668789B1 (ko) |
CN (1) | CN113194965A (ko) |
AU (1) | AU2019383263B2 (ko) |
SG (1) | SG11202105231UA (ko) |
WO (1) | WO2020106074A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3884951A4 (en) * | 2018-11-23 | 2022-11-09 | Medicosbiotech, Inc. | COMPOSITION FOR THE TREATMENT OF HAIR LOSS OR FOR THE STIMULATION OF HAIR GROWTH |
Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5183805A (en) | 1990-08-13 | 1993-02-02 | Board Of Regents, The University Of Texas System | Bioactive egf peptides for promotion of tissue regeneration and cancer therapy |
JPH0570365B2 (ko) | 1984-05-18 | 1993-10-05 | Hitachi Ltd | |
US5264207A (en) | 1989-07-18 | 1993-11-23 | Exsymol S.A.M. | Products for cutaneous applications with cosmetic and/or therapeutic effects |
EP0575484A1 (en) | 1991-03-12 | 1993-12-29 | Creative Biomolecules, Inc. | Method for promoting tissue repair and regeneration |
WO1994013333A1 (en) | 1992-12-08 | 1994-06-23 | University College Cardiff Consultants Limited | Wound dressings |
WO1996013164A1 (en) | 1994-10-28 | 1996-05-09 | University Of Akron, The | Polymeric wound healing accelerators |
WO1996030038A1 (en) | 1995-03-29 | 1996-10-03 | The Rockefeller University | Peptide growth factor having epidermal inducing activity |
US5897880A (en) | 1995-09-29 | 1999-04-27 | Lam Pharmaceuticals, Llc. | Topical drug preparations |
US5981606A (en) | 1991-03-01 | 1999-11-09 | Warner-Lambert Company | Therapeutic TGF-beta-wound healing compositions and methods for preparing and using same |
WO2000024378A1 (en) | 1998-10-23 | 2000-05-04 | Polyheal Ltd | Compositions of microspheres for wound healing |
US6165978A (en) | 1997-12-12 | 2000-12-26 | University Of Southern California | Wound healing composition |
KR100315168B1 (ko) | 1999-01-28 | 2001-11-30 | 대한민국(관리청:특허청장, 승계청:농촌진흥청장) | 창상피복용 견 피브로인 단백질 스폰지막의 제조방법 |
KR100518152B1 (ko) | 2002-05-09 | 2005-09-29 | 메디제네스(주) | 혈장 또는 혈청을 함유한 창상 치료용 약학 조성물 |
KR20070113876A (ko) | 2006-05-26 | 2007-11-29 | 메디제네스(주) | 혈장성분을 함유하는 창상 치료용 약학 조성물 |
US20130172999A1 (en) * | 2010-06-09 | 2013-07-04 | Trustees Of Tufts College | Multilayered silk scaffolds for meniscus tissue engineering |
KR101317420B1 (ko) | 2010-03-11 | 2013-10-10 | 한국과학기술원 | 고분자량의 재조합 실크 또는 실크 유사 단백질 및 이를 이용하여 제조된 마이크로 또는 나노 크기의 거미줄 또는 거미줄 유사 섬유 |
KR20150061806A (ko) * | 2013-11-28 | 2015-06-05 | 중부대학교 | 활성화된 혈소판 풍부 혈장을 유효성분으로 포함하는 동물의 창상 치료용 수의학적 조성물 |
KR101617075B1 (ko) | 2014-01-24 | 2016-04-29 | 충남대학교산학협력단 | 수화겔형 실크 피브로인 창상피복재 및 그 제조방법 |
US20160235889A1 (en) * | 2013-09-27 | 2016-08-18 | Tufts University | Silk/platelet composition and use thereof |
US20170354754A1 (en) * | 2016-06-10 | 2017-12-14 | Brock Liden | Systems and methods for treating a wound with wound packing |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4957742A (en) * | 1984-11-29 | 1990-09-18 | Regents Of The University Of Minnesota | Method for promoting hair growth |
-
2018
- 2018-11-23 KR KR1020180146287A patent/KR102668789B1/ko active IP Right Grant
-
2019
- 2019-11-21 AU AU2019383263A patent/AU2019383263B2/en active Active
- 2019-11-21 JP JP2021529098A patent/JP7309872B2/ja active Active
- 2019-11-21 SG SG11202105231UA patent/SG11202105231UA/en unknown
- 2019-11-21 US US17/296,301 patent/US20220008463A1/en active Pending
- 2019-11-21 EP EP19888039.5A patent/EP3884952A4/en active Pending
- 2019-11-21 WO PCT/KR2019/016011 patent/WO2020106074A1/ko unknown
- 2019-11-21 CN CN201980083434.3A patent/CN113194965A/zh active Pending
Patent Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0570365B2 (ko) | 1984-05-18 | 1993-10-05 | Hitachi Ltd | |
US5264207A (en) | 1989-07-18 | 1993-11-23 | Exsymol S.A.M. | Products for cutaneous applications with cosmetic and/or therapeutic effects |
US5183805A (en) | 1990-08-13 | 1993-02-02 | Board Of Regents, The University Of Texas System | Bioactive egf peptides for promotion of tissue regeneration and cancer therapy |
US5981606A (en) | 1991-03-01 | 1999-11-09 | Warner-Lambert Company | Therapeutic TGF-beta-wound healing compositions and methods for preparing and using same |
EP0575484A1 (en) | 1991-03-12 | 1993-12-29 | Creative Biomolecules, Inc. | Method for promoting tissue repair and regeneration |
WO1994013333A1 (en) | 1992-12-08 | 1994-06-23 | University College Cardiff Consultants Limited | Wound dressings |
WO1996013164A1 (en) | 1994-10-28 | 1996-05-09 | University Of Akron, The | Polymeric wound healing accelerators |
WO1996030038A1 (en) | 1995-03-29 | 1996-10-03 | The Rockefeller University | Peptide growth factor having epidermal inducing activity |
US5897880A (en) | 1995-09-29 | 1999-04-27 | Lam Pharmaceuticals, Llc. | Topical drug preparations |
US6165978A (en) | 1997-12-12 | 2000-12-26 | University Of Southern California | Wound healing composition |
WO2000024378A1 (en) | 1998-10-23 | 2000-05-04 | Polyheal Ltd | Compositions of microspheres for wound healing |
KR100315168B1 (ko) | 1999-01-28 | 2001-11-30 | 대한민국(관리청:특허청장, 승계청:농촌진흥청장) | 창상피복용 견 피브로인 단백질 스폰지막의 제조방법 |
KR100518152B1 (ko) | 2002-05-09 | 2005-09-29 | 메디제네스(주) | 혈장 또는 혈청을 함유한 창상 치료용 약학 조성물 |
KR20070113876A (ko) | 2006-05-26 | 2007-11-29 | 메디제네스(주) | 혈장성분을 함유하는 창상 치료용 약학 조성물 |
KR101317420B1 (ko) | 2010-03-11 | 2013-10-10 | 한국과학기술원 | 고분자량의 재조합 실크 또는 실크 유사 단백질 및 이를 이용하여 제조된 마이크로 또는 나노 크기의 거미줄 또는 거미줄 유사 섬유 |
US20130172999A1 (en) * | 2010-06-09 | 2013-07-04 | Trustees Of Tufts College | Multilayered silk scaffolds for meniscus tissue engineering |
US20160235889A1 (en) * | 2013-09-27 | 2016-08-18 | Tufts University | Silk/platelet composition and use thereof |
KR20150061806A (ko) * | 2013-11-28 | 2015-06-05 | 중부대학교 | 활성화된 혈소판 풍부 혈장을 유효성분으로 포함하는 동물의 창상 치료용 수의학적 조성물 |
KR101617075B1 (ko) | 2014-01-24 | 2016-04-29 | 충남대학교산학협력단 | 수화겔형 실크 피브로인 창상피복재 및 그 제조방법 |
US20170354754A1 (en) * | 2016-06-10 | 2017-12-14 | Brock Liden | Systems and methods for treating a wound with wound packing |
Non-Patent Citations (4)
Title |
---|
BLAUG, SEYMOUR: "Remington's Pharmaceutical Science", 1975, MACK PUBLISHING COMPANY |
NISHIDA, LARCH, OPHTHALMOLOGY, vol. 101, 1983, pages 1046 |
See also references of EP3884952A4 |
WYSOCKI ET AL., ARCH. DERMATOL., vol. 124, 1988, pages 175 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3884951A4 (en) * | 2018-11-23 | 2022-11-09 | Medicosbiotech, Inc. | COMPOSITION FOR THE TREATMENT OF HAIR LOSS OR FOR THE STIMULATION OF HAIR GROWTH |
Also Published As
Publication number | Publication date |
---|---|
SG11202105231UA (en) | 2021-06-29 |
JP2022513123A (ja) | 2022-02-07 |
AU2019383263B2 (en) | 2022-09-29 |
JP7309872B2 (ja) | 2023-07-18 |
CN113194965A (zh) | 2021-07-30 |
US20220008463A1 (en) | 2022-01-13 |
EP3884952A4 (en) | 2022-08-03 |
KR102668789B1 (ko) | 2024-05-24 |
KR20200060997A (ko) | 2020-06-02 |
AU2019383263A1 (en) | 2021-07-08 |
EP3884952A1 (en) | 2021-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100518152B1 (ko) | 혈장 또는 혈청을 함유한 창상 치료용 약학 조성물 | |
KR101019188B1 (ko) | 불완전한 조직 복구를 치료하기 위한 조성물 및 최소 침습방법 | |
US20090317439A1 (en) | Cell Preparations for Extemporaneous Use, Useful for Healing and Rejuvenation In Vivo | |
IE852810L (en) | Wound healing agents | |
CN105030826A (zh) | 一种复合型血小板凝胶及其制备方法 | |
Santhanam et al. | Bovine based collagen dressings in wound care management | |
KR20070113876A (ko) | 혈장성분을 함유하는 창상 치료용 약학 조성물 | |
Chiu et al. | Tissue engineering-based strategies for diabetic foot ulcer management | |
WO2020106074A1 (ko) | 창상치료용 약학조성물 | |
WO2017030388A1 (ko) | 피부 상처 치료조성물 | |
WO2017082441A1 (ko) | 활성화된 혈소판 풍부 혈장을 유효성분으로 포함하는 동물의 창상 치료용 수의학적 조성물 | |
RU2657806C2 (ru) | Способ регионального лечения трофической язвы | |
Al-Anaaz et al. | Study the effect of innovative advance method for accelerating wound healing in male rabbit model. | |
JP4578067B2 (ja) | 局所医薬組成物 | |
Aswany et al. | A Concise Review on Scarless Wound Healing | |
JPH0720873B2 (ja) | 創傷治癒剤 | |
RU2301069C2 (ru) | Способ лечения осложненных форм варикозной и посттромбофлебитической болезней | |
RU2687007C2 (ru) | Способ биотехнологического восстановления кожного покрова аллогенными стволовыми клетками человека | |
Rubio et al. | Clinical applications of plasma growth factors | |
Slonkova et al. | Successful treatment of chronic venous leg ulcers with lyophilized cultured epidermal allografts | |
JP2004161649A (ja) | 生体組織修復剤およびその製造方法 | |
WO2024110937A1 (en) | Compositions based on a mixture of bioactive molecules and exosomes for use in the treatment of conditions requiring tissue repair and regeneration | |
CN117157086A (zh) | 皮肤瘢痕的治疗 | |
Nath | A Clinical Study on the Efficacy of Autologous Platelet Rich Plasma in the Management of Chronic Non Healing Ulcers | |
Goldstein et al. | Advances in the basic and clinical applications of thymosin b4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19888039 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021529098 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2019888039 Country of ref document: EP Effective date: 20210623 |
|
ENP | Entry into the national phase |
Ref document number: 2019383263 Country of ref document: AU Date of ref document: 20191121 Kind code of ref document: A |